Q1 EPS Forecast for Bicara Therapeutics Raised by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Investment analysts at HC Wainwright boosted their Q1 2026 earnings estimates for Bicara Therapeutics in a research note issued on Tuesday, March 31st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.64) for the quarter, up from their prior estimate of ($0.72). HC Wainwright has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.56) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.04.

Other research analysts have also issued reports about the stock. Citigroup began coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. The Goldman Sachs Group raised their price target on Bicara Therapeutics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday. Bank of America began coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Wells Fargo & Company upped their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Eight research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Bicara Therapeutics Price Performance

Shares of Bicara Therapeutics stock opened at $20.50 on Thursday. Bicara Therapeutics has a 1-year low of $7.80 and a 1-year high of $21.05. The business has a 50-day moving average of $17.28 and a 200-day moving average of $16.69. The company has a market capitalization of $1.34 billion, a PE ratio of -8.10 and a beta of -1.24.

Insider Buying and Selling

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 17,392 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $18.16, for a total transaction of $315,838.72. Following the completion of the sale, the chief operating officer directly owned 205,141 shares of the company’s stock, valued at approximately $3,725,360.56. This represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.22, for a total transaction of $246,972.10. Following the completion of the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,648,368.10. This trade represents a 8.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 137,969 shares of company stock worth $2,586,198. Company insiders own 15.50% of the company’s stock.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG raised its holdings in shares of Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after acquiring an additional 1,171 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after purchasing an additional 1,474 shares during the last quarter. Mariner LLC grew its stake in shares of Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after purchasing an additional 1,902 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Bicara Therapeutics by 13.2% in the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares in the last quarter.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Wall Street analyst consensus implies a large upside (~54.9%) to BCAX based on average price targets and improving earnings-estimate revisions, a factor traders cite as justification for buying interest. Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here’s is How to Trade
• Positive Sentiment: Clinical progress: Seeking Alpha reiterates a Buy rating as BCAX advances its pivotal phase 3 FORTIFI-HN01 study; strong phase 1/1b signals (12?month OS 61%, ORR 54% with ficerafusp alfa + KEYTRUDA) support the program. Key upcoming catalysts: phase?3 interim readout mid?2027 and long?term phase 1b follow?up at ASCO 2026. Near?full enrollment expected by year?end. Bicara: Maintaining ‘Buy’ Rating On Ficerafusp Alfa Phase 3 Advancement
• Positive Sentiment: Q4 / cash position: Earnings call highlights show a stronger cash position and a slight beat on Q4 EPS vs. estimates, which reduces near?term dilution risk and supports runway for clinical execution. Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full Q4 earnings call transcript is available for investors digging into management comments on timelines and cash burn; useful for detailed diligence but not a single price driver by itself. Q4 2025 earnings call transcript
• Negative Sentiment: Mixed analyst views: Goldman Sachs raised its PT to $16 (neutral) and Wells Fargo to $16 (equal?weight)—both targets sit well below the current market price, implying downside from their perspective. These conservative calls can cap near?term upside and add volatility. Benzinga coverage of analyst moves
• Positive Sentiment: Other broker support remains bullish: Wedbush (outperform, $30 PT), Citizens Jmp (market outperform, $31 PT) and HC Wainwright (buy, PT $42) provide higher upside scenarios that likely underlie investor optimism. Benzinga coverage of analyst moves

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.